SION: Dual combination SION-451 + SION-2222 showed promising safety and efficacy, advancing to Phase 2a
Post hoc analysis of the PreciSION CF Phase 2a trial revealed that removing confounded participants showed evidence of NBD1 target engagement, with a mean sweat chloride reduction of up to -8.6 mmol/L. The preferred dual combination, SION-451 + SION-2222, demonstrated favorable safety and is advanc…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.